Mexiletine carbonyloxy β-D-glucuronide: a novel metabolite in human urine

Reference

• ABOLFATHI, Z., FISET, C., GILBERT, M., MOERIKE, K., BELANGER, P. M. and TURGEON, J., 1993, Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans. Journal of Pharmacology and Experimental Therapeutics, 266, 1196–1201.
   PubMed Web of Science ®Google Scholar
• BECKETT, A. H. and CHIDOMERE, E. C., 1977, The identification and analysis of mexiletine and its metabolic products in man. Journal of Pharmacy and Pharmacology, 29, 281–285.
   PubMed Web of Science ®Google Scholar
• BROLY, F., VANDAMME, N., LIBERSA, C. and LHERMITTE, M., 1991, The metabolism of mexiletine in relation to the debrisoquine/spartein-type polymorphism of drug oxidation. British Journal of Clinical Pharmacology, 32, 459–466.
   PubMed Web of Science ®Google Scholar
• BROWN, S. Y., GARLAND, W. A. and FUKUDA, E. K., 1990, Isolation and characterization of an unusual glucuronide conjugate of rimantadine. Drug Metabolism and Disposition, 18, 546–547.
   PubMed Web of Science ®Google Scholar
• CAMPBELL, N. P. S., KELLY, J. G., ADGEY, A. A. J. and SHANKS, R. G., 1978, The clinical pharmacology of mexiletine. British Journal of Clinical Pharmacology, 6, 103–108.
   Google Scholar
• CROOKS, J. E. and DONNELLAN, J. P., 1989, Kinetics and mechanism of the reaction between carbon dioxide and amines in aqueous solution. Journal of the Chemical Society Perkin Transactions, 2, 331–333.
   Web of Science ®Google Scholar
• Dow, J., PIRIOU, F., WOLF, E., DULERY, B. D. and HAEGELE, K. D., 1994, Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans. Drug Metabolism and Disposition, 22, 738–749.
   PubMedGoogle Scholar
• ELVIN, A. T., KEENAGHAN, J. B., BYRNES, E. W., TENTHOREY, P. A., MCMASTER, P. D., TAKMAN, B. H., LALKA, D., MEYER, M. B. and RONFELD, R. A., 1980, Tocainide conjugation in humans: novel biotransformation pathway for a primary amine. Journal of Pharmaceutical Sciences, 69, 47–49.
   PubMed Web of Science ®Google Scholar
• GROS, G., ROLLEMA, H. S. and FORSTER, R. E., 1981, The carbamate equilibrium of a- and E-amino groups of human haemoglobin at 37°C. Journal of Biological Chemistry, 256, 5471–5480.
   PubMedGoogle Scholar
• HAESELBARTH, V., DOEVENDANS, J. E. and WOLF, M., 1981, Kinetics and bioavailability of mexiletine in healthy subjects. Clinical Pharmacological Therapy, 29, 729–736.
   PubMedGoogle Scholar
• KILMARTIN, J. V. and ROSSI-BERNARDI, I., 1973, Interaction of hemoglobin with hydrogen ions, carbon dioxide, and organic phosphates. Physiological Review, 53, 836–890.
   Google Scholar
• KWOK, D. W. K., PILLAI, G., VAUGHAN, R., AXELSON, J. E. and MCERLANE, K. M., 1990, Preparative high-performance liquid chromatography and preparative thin-layer chromatography isolation of tocainide carbamoy1-0-13-d-glucuronide: Structural characterization by gas chromatography-mass spectrometry and fast atom bombardment-mass spectrometry. Journal of Pharmaceutical Sciences, 79, 857–861.
   Google Scholar
• LLEDO, P., ABRAMS, S. M. L., JOHNSTON, A., PATEL, M., PEARSON, R. M. and TURNER, P. 1993, Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. European Journal of Clinical Pharmacology, 44, 63–67.
   Google Scholar
• MURRAY, K. T., BARBEY, J. T., KOPELMAN, H. A., SIDDOWAY, L. A., ECHT, D. S., WOOSLEY, R. L. and RODEN, D. M., 1989, Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects and predictive value of lidocaine testing. Clinical Pharmacological Therapy, 45, 553–561.
   PubMedGoogle Scholar
• MYERS, T. G. and NELSON, S. D., 1990, Neuroactive carbamate adducts of fl-N-methylamino-L-alanine and ethylenediamine. Journal of Biological Chemistry, 265, 10193–10195.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA, M., KOBAYASHI, K., SHIMADA, N., TOKUDOME, S., YAMAMOTO, T. and KUROIWA, Y., 1998, Involvement of CYP1A2 in mexiletine metabolism. British Journal of Clinical Pharmacology, 46, 55–62.
   PubMed Web of Science ®Google Scholar
• PENTIKAINEN, P. J., HALINEN, M. 0. and HELIN, M. J., 1983, Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction. European Journal of Clinical Pharmacology, 25, 773–777.
   Google Scholar
• PRESCOTT, L. F., POTTAGE, A. and CLEMENTS, J. A., 1977, Absorption, distribution and elimination of mexiletine. Postgraduate Medical Journal, 53, 50–55.
   PubMedGoogle Scholar
• SCHAEFER, W. H., 1992, Formation of a carbamoyl glucuronide conjugate of carvedilol in vitro using dog and rat liver microsomes. Drug Metabolism and Disposition, 20, 130–133.
   PubMedGoogle Scholar
• SENDA, C., YAMAURA, Y., KOBAYASHI, K., FUJI, H., MINAMI, H., SASAKI, Y., IGARASHI, T. and CHIBA, K., 2001, Influence of the C YP2D6*10 allele on the metabolism of mexiletine by human liver microsomes. British Journal of Clinical Pharmacology, 52, 100–103.
   PubMed Web of Science ®Google Scholar
• TURGEON, J., FISET, C., GIGUERE, R., GILBERT, M., MOERIKE, K., ROULEAU, J. R., KROMER, H. K., EICHELBAU M., GRECH-BELANGER, 0. and BELANGER, P. M., 1991, Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. Journal of Pharmacology and Experimental Therapeutics, 259, 789–798.
   Google Scholar
• TURGEON, J., PARE, J. R. J., LALANDE, M., GRECH-BELANGER, 0. and BELANGER, P. M., 1992, Isolation and structural characterization by spectroscopic methods of two glucuronide metabolites of mexiletine after N-oxidation and deamination. Drug Metabolism and Disposition, 20, 762–769.
   Google Scholar
• UENO, K., TAMAMURA, A., MATSUMOTO, K., KOMAMURA, K., KAMAKURA, S., MIYATAKE, K. and SHIBAKAWA, M., 2002, Evaluation of mexiletine clearance in a Japanese population. Annals of Pharmacotherapy, 36, 241–245.
   PubMedGoogle Scholar